Evidence map›Paper›PMID 31623241›Full record

ReviewPharmaceuticals (Basel, Switzerland)2019

Computer-Assisted and Data Driven Approaches for Surveillance, Drug Discovery, and Vaccine Design for the Zika Virus.

Subhash C Basak, Subhabrata Majumdar, Ashesh Nandy, Proyasha Roy, Tathagata Dutta, Marjan Vracko, Apurba K Bhattacharjee

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review of advanced research on swineFrontiers in immunology · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Digital microbiology.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2020
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Subhash C BasakDepartment of Chemistry and Biochemistry, University of Minnesota, Duluth, MN 55812, USA. sbasak@d.umn.edu.
Subhabrata MajumdarUniversity of Florida Informatics Institute, Gainesville, FL 32601, USA. subho@research.att.com.ORCID 0000-0003-3529-7820
Ashesh NandyCentre for Interdisciplinary Research and Education, Kolkata 700068, India. anandy43@yahoo.com.ORCID 0000-0002-1649-7731
Proyasha RoyCentre for Interdisciplinary Research and Education, Kolkata 700068, India. proyasha.roy@gmail.com.
Tathagata DuttaCentre for Interdisciplinary Research and Education, Kolkata 700068, India. tathagata.dk@gmail.com.
Marjan VrackoNational Institute of Chemistry, Hajdrihova 19, Ljubljana 1000, Slovenia. marjan.vracko@ki.si.
Apurba K BhattacharjeeBiomedical Graduate Research Organization, Department of Microbiology and Immunology School of Medicine, Georgetown University, Washington, DC 20057, USA. ab3094@georgetown.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human life has been at the edge of catastrophe for millennia due diseases which emerge and reemerge at random. The recent outbreak of the Zika virus (ZIKV) is one such menace that shook the global public health community abruptly. Modern technologies, including computational tools as well as experimental approaches, need to be harnessed fast and effectively in a coordinated manner in order to properly address such challenges. In this paper, based on our earlier research, we have proposed a four-pronged approach to tackle the emerging pathogens like ZIKV: (a) Epidemiological modelling of spread mechanisms of ZIKV; (b) assessment of the public health risk of newly emerging strains of the pathogens by comparing them with existing strains/pathogens using fast computational sequence comparison methods; (c) implementation of vaccine design methods in order to produce a set of probable peptide vaccine candidates for quick synthesis/production and testing in the laboratory; and (d) designing of novel therapeutic molecules and their laboratory testing as well as validation of new drugs or repurposing of drugs for use against ZIKV. For each of these stages, we provide an extensive review of the technical challenges and current state-of-the-art. Further, we outline the future areas of research and discuss how they can work together to proactively combat ZIKV or future emerging pathogens.

Indexed as

2D graphical methodcomputer-assisted anti-Zika drug discoverymahalanobis distanceneighborhood matrixpeptide vaccine designprincipal component analysis (PCA)SIR modelsviral epidemicsZika virus (ZIKV)

Identifiers

PMID31623241
PMCPMC6958466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.